natgillin/translations-raw huggingface dataset:
There is a moderate amount of data from the use of Fluenz Tetra in pregnant women. 
Obstaja zmerna količina podatkov o uporabi cepiva Fluenz Tetra pri nosečnicah.
Frequency and duration of vaccine virus shedding in these immunocompromised children and adolescents were comparable to that seen in healthy children and adolescents. 
Pogostost in trajanje izločanja cepnega virusa pri teh imunsko oslabelih otrocih in mladostnikih sta bili primerljivi z zdravimi otroci in mladostniki.
However, this alteration might not be of clinical relevance with the two dose immunisation schedule of the rubella vaccine. 
Vendar pa morda ta sprememba ni klinično pomembna pri režimu imunizacije z dvema odmerkoma cepiva proti rdečkam.
Africa, Latin America 
Afrika, Južna Amerika
Fluenz Tetra should not be administered to children and adolescents with severe asthma or active wheezing because these individuals have not been adequately studied in clinical studies. 
Cepiva Fluenz Tetra ne smete uporabljati pri otrocih in mladostnikih s hudo astmo ali aktivnim sopenjem, saj te osebe niso bile ustrezno preučene v kliničnih študijah.
fewer cases than injectable fewer cases than injectable 
manj primerov kot pri cepivu, ki se injicira manj primerov kot pri cepivu, ki se injicira
Prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. 
Preprečevanje gripe pri otrocih in mladostnikih od 24 mesecev do manj kot 18 let.
In circumstances where contact with severely immunocompromised individuals is unavoidable, the potential risk of transmission of the influenza vaccine virus should be weighed against the risk of acquiring and transmitting wild-type influenza virus. 
V okoliščinah, kjer stika s hudo imunsko oslabljenimi osebami ni mogoče preprečiti, je treba pretehtati tveganje možnosti prenosa virusa iz cepiva proti gripi glede na tveganje pridobitve ter prenosa virusa gripe divjega tipa.
- Hypersensitivity to the active substances, to any of the excipients listed in section 6.1 (e.g. gelatin), or to gentamicin (a possible trace residue). 
- Preobčutljivost na učinkovino, katero koli pomožno snov, navedeno v poglavju 6.1 (npr. želatino) ali gentamicin (možen ostanek v sledeh).
Fluenz's efficacy data in the paediatric population consist of 9 controlled studies comprising over 20,000 infants and toddlers, children and adolescents, conducted during 7 influenza seasons. 
Podatki o učinkovitosti cepiva Fluenz v pediatrični populaciji so sestavljeni iz 9 kontroliranih študij, ki so zajele več kot 20.000 dojenčkov in malčkov, otrok in mladostnikov in so se izvajale v 7 sezonah gripe.
• Check the appearance of the vaccine before administration. 
• Pred uporabo preverite videz cepiva.
6 to 59 M 7,852 2004-2005 
6 do 59 m 7.852 2004 - 2005
While animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity, and post-marketing data offer some reassurance in the event of inadvertent administration of the vaccine, Fluenz Tetra is not recommended during pregnancy. 
Čeprav študije na živalih ne kažejo neposrednih ali posrednih škodljivih učinkov na sposobnost razmnoževanja in podatki iz obdobja po začetku trženja dajejo pomirjujoče informacije v primeru nenamernega dajanja cepiva, Fluenz Tetra ne uporabljajte pri nosečnicah.
D153-P502 Europe 6 to 35 M 1,616 
D153-P502 Evropa 6 do 35 m 1.616
USA, Europe, Asia/Oceania 
ZDA, Evropa, Azija/ Oceanija
Although safety in children and adolescents with mild to moderate asthma has been established, data in children with other pulmonary diseases or with chronic cardiovascular, metabolic or renal diseases are limited. 
Čeprav so ugotavljali varnost pri otrocih in mladostnikih z blago do zmerno astmo, so podatki pri otrocih z drugimi pljučnimi boleznimi ali s kroničnimi kardiovaskularnimi, presnovnimi ali ledvičnimi boleznimi pomanjkljivi.
11 to 24 M 1,150 2002-2003 
11 do 24 m 1.150 2002 - 2003
Do not use this vaccine after the expiry date which is stated on the applicator label after the letters EXP. 
Tega cepiva ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki nosnika poleg oznake EXP.
Prepare the applicator Remove rubber tip protector. 
Pripravite nosnik Odstranite gumijasto zaščito konice.
The influenza virus strains in Fluenz Tetra are (a) cold-adapted (ca); (b) temperature-sensitive (ts); and (c) attenuated (att). 
Sevi virusa gripe v cepivu Fluenz Tetra so (a) hladno-prilagojeni (cold-adapted, ca); (b) občutljivi na temperaturo (temperature-sensitive, ts); in (c) oslabljeni (attenuated, att).
Other medicines, other vaccines and Fluenz Tetra 
Druga zdravila, druga cepiva in cepivo Fluenz Tetra
Fluenz Tetra should not be used in infants and toddlers below 24 months of age because of safety concerns regarding increased rates of hospitalisation and wheezing in this population (see section 4.8). 
Cepiva Fluenz Tetra se ne sme uporabljati pri dojenčkih in malčkih, mlajših od 24 mesecev zaradi pomislekov glede varnosti zaradi povečane stopnje hospitalizacije in sopenja pri tej populaciji (glejte poglavje 4.8).
Number of Study Participants 
Število sodelujočih v študiji
Nasal spray, suspension 
pršilo za nos, suspenzija
Metabolism and nutrition disorders Very common: Decreased appetite 
Presnovne in prehranske motnje Zelo pogosti: zmanjšan apetit
However, a conclusion on clinical benefit of this vaccine in adults could not be made given that results observed in some studies versus injectable influenza vaccines were suggestive of a lower efficacy of Fluenz. 
Vendar pa sklepanja o kliničnih koristih tega cepiva pri odraslih niso mogoča, ker kažejo rezultati nekaterih študij, kjer so cepivo primerjali s cepivi proti gripi, ki se injicirajo, manjšo učinkovitost cepiva Fluenz.
Adult studies 
Študije pri odraslih
However, based upon the potential for influenza antiviral agents to reduce the effectiveness of Fluenz Tetra, it is recommended not to administer the vaccine until 48 hours after the cessation of influenza antiviral therapy. 
Vendar pa se zaradi potenciala protivirusnih zdravil proti gripi za zmanjšanje učinkovitosti cepiva Fluenz Tetra ne priporoča uporabe cepiva do 48 ur po končanem protivirusnem zdravljenju proti gripi.
12 to 35 M 2,764 
12 do 35 m 2.764
EU/1/13/887/002 <1 sprayer> EU/1/13/887/001 <10 sprayers> EU/1/13/887/003 <1 sprayer> EU/1/13/887/004 <10 sprayers> 
EU/1/13/887/002 <1 pršilnik> EU/1/13/887/001 <10 pršilnikov> EU/1/13/887/003 <1 pršilnik> EU/1/13/887/004 <10 pršilnikov>
In studies of adults in which a high percentage of individuals had underlying chronic medical conditions, the safety profile of trivalent Fluenz was comparable to the safety profile observed in individuals without these conditions. 
V študijah z odraslimi, kjer je imel velik odstotek oseb obstoječo kronično bolezen, je bil varnostni profil trivalentnega cepiva Fluenz primerljiv z varnostnim profilom, ki so ga opazili pri osebah brez teh bolezni.
Fluenz Tetra is not contraindicated for use in individuals with asymptomatic HIV infection; or individuals who are receiving topical/inhaled corticosteroids or low-dose systemic corticosteroids or those receiving corticosteroids as replacement therapy, e.g. for adrenal insufficiency. 
Uporaba cepiva Fluenz Tetra ni kontraindicirana pri osebah z asimptomatsko okužbo z virusom HIV; ali osebah, ki prejemajo lokalne/inhalacijske kortikosteroide ali nizkoodmerne sistemske kortikosteroide ter pri tistih, ki prejemajo kortikosteroide kot nadomestno zdravljenje, npr. pri insuficienci nadledvične žleze.
The primary circulating strain was antigenically dissimilar from the H3N2 strain represented in the vaccine; efficacy against the mismatched A/H3N2 strain was 85.9% (95% CI: 75.3, 91.9). 
Primarni sev, ki je krožil, je bil antigensko različen od seva H3N2 v cepivu; učinkovitost proti neujemajočem se sevu A/H3N2 je bila 85,9 % (95-% IZ: 75,3; 91,9).
No adverse effects on HIV viral load or CD4 counts were identified following trivalent Fluenz administration. 
Nobenih negativnih učinkov na virusno breme HIV ali na število celic CD4 ni bilo ugotovljenih po dajanju trivalentnega cepiva Fluenz.
Name and address of the manufacturer of the biological active substances 
Ime in naslov izdelovalca biološke zdravilne učinkovine
As with most vaccines, appropriate medical treatment and supervision should always be readily available to manage an anaphylactic event or serious hypersensitivity event following the administration of Fluenz Tetra. 
Kot pri vseh cepivih je treba nemudoma zagotoviti ustrezno obliko zdravljenja in zdravniškega nadzora za obvladovanje anafilaktičnega dogodka ali dogodka resne preobčutljivosti po uporabi cepiva Fluenz Tetra.
Study Number 
Številka študije
Therefore, as some viruses are excreted in human milk, Fluenz Tetra should not be used during breast-feeding. 
Ker se nekateri virusi izločajo v materino mleko, se cepiva Fluenz Tetra med dojenjem ne sme uporabljati.
The most common adverse reaction observed in clinical studies was nasal congestion/rhinorrhoea. 
Najpogostejši neželeni učinek, opažen v kliničnih študijah, je bil zamašen nos/rinoreja.
A total of 2,312 children and adolescents were randomised by site at a 3:1:1 ratio to receive either Fluenz Tetra or one of two formulations of comparator vaccine Fluenz, each containing a B strain that corresponded to one of the two B strains in Fluenz Tetra (a B strain of the Yamagata lineage and a B strain of the Victoria lineage). 
Skupno 2.312 otrok in mladostnikov je bilo randomiziranih v razmerju 3:1:1, pri čemer so prejeli cepivo Fluenz Tetra ali eno od obeh primerjalnih cepiv Fluenz, od katerih je vsako vsebovalo sev B, ki je odgovarjal enemu od obeh sevov B v cepivu Fluenz Tetra (sev B v liniji Yamagata in sev B v liniji Victoria).
Vaccine recipients should be informed that Fluenz Tetra is an attenuated live virus vaccine and has the potential for transmission to immunocompromised contacts. 
Prejemnike cepiva je treba obvestiti, da je cepivo Fluenz Tetra cepivo z oslabljenim živim virusom in ima potencial za prenos na imunsko oslabljene osebe.
Fluenz Tetra will be administered under the supervision of a doctor, nurse or pharmacist. 
Cepivo Fluenz Tetra boste prejeli pod nadzorom zdravnika, medicinske sestre ali farmacevta.
Reduction in culture-confirmed influenza illness relative to placebo. 
Zmanjšanje obolelosti za gripo, potrjene s kulturo, glede na placebo.
He or she will decide if Fluenz Tetra is suitable for you. 
Odločil/-a se bo, ali je cepivo Fluenz Tetra za vas primerno.
Fluenz Tetra vaccine viruses are grown in chicken eggs. 
Virusi za cepiva Fluenz Tetra proti gripi se vzgajajo v piščančjih jajcih.
- Children and adolescents with clinical immunodeficiency due to conditions or immunosuppressive therapy such as: acute and chronic leukaemias; lymphoma; symptomatic HIV infection; cellular immune deficiencies; and high-dose corticosteroids. 
- Otroci in mladostniki s klinično imunodeficienco zaradi bolezni ali imunosupresivnega zdravljenja kot: akutne in kronične oblike levkemije; limfom; simptomatska okužba z virusom HIV; celična imunodeficienca in uporaba kortikosteroidov v visokih odmerkih.
In an active-controlled clinical study (MI-CP111), an increased rate of hospitalisations (for any cause) through 180 days after final vaccination dose was observed in infants and toddlers 6-11 months of age (6.1% Fluenz versus 2.6% injectable influenza vaccine). 
V aktivni kontrolirani klinični študiji (MI-CP111) so opazili povečano stopnjo hospitalizacij (zaradi vseh razlogov) v obdobju 180 dni po končnem odmerku vakcinacije pri dojenčkih in malčkih starih od 6 - 11 mesecev (6,1 % cepivo Fluenz v primerjavi z 2,6 % cepivo proti gripi, ki se injicira).
What Fluenz Tetra is and what it is used for 
Kaj je zdravilo Fluenz Tetra in za kaj ga uporabljamo
In clinical studies, the safety profile of Fluenz Tetra was similar to the safety profile of Fluenz. 
V kliničnih študijah je bil varnostni profil cepiva Fluenz Tetra podoben varnostnemu profilu cepiva Fluenz.
What you need to know before you are given Fluenz Tetra 
Kaj morate vedeti, preden boste prejeli cepivo Fluenz Tetra
• Do not use Fluenz Tetra if the expiry date has passed or the sprayer appears damaged, for example, if the plunger is loose or displaced from the sprayer or if there are any signs of leakage. 
• Cepiva Fluenz Tetra ne smete uporabljati, če mu je potekel rok uporabnosti ali če opazite, da je pršilnik poškodovan, na primer če bat ne tesni ali izpade iz pršilnika ali opazite kakršnekoli znake iztekanja tekočine.
Tell your doctor, nurse or pharmacist if the person being vaccinated is taking, has recently taken or might take any other medicines, including medicines that do not require a prescription. 
Obvestite zdravnika, farmacevta ali medicinsko sestro, če oseba, ki se cepi, jemlje, je pred kratkim jemala ali pa bo morda začela jemati katero koli drugo zdravilo.
The rate of hospitalisations was not increased in Fluenz recipients 12 months and older. 
Stopnja hospitalizacije se pri prejemnikih cepiva Fluenz starih 12 mesecev ali več ni povišala.
- Children and adolescents younger than 18 years of age receiving salicylate therapy because of the association of Reye's syndrome with salicylates and wild-type influenza infection. 
- Otroci in mladostniki stari manj kot 18 let, ki se zdravijo s salicilatom zaradi povezave z Reyevim sindromom pri uporabi salicilatov in okužbo z gripo virusa divjega tipa.
Clinical experience with Fluenz is relevant to Fluenz Tetra because both vaccines are manufactured using the same process and have overlapping compositions. 
Klinične izkušnje s cepivom Fluenz so pomembne za cepivo Fluenz Tetra, saj sta obe cepivi izdelani po enakem postopku in imata prekrivajoče sestavine.
In clinical studies with the vaccine, most side effects were mild in nature and short term. 
Pri kliničnih študijah cepiva je bila večina neželenih učinkov blaga in kratkotrajna.
The incidence of wheezing within 15 days after vaccination was lower in Fluenz recipients relative to inactivated vaccine recipients (19.5% vs. 23.8%, P=0.02). 
Pojavnost sopenja v 15 dneh po cepljenju je bila nižja pri preiskovancih, ki so prejeli cepivo Fluenz kot pri preiskovancih, ki so prejeli inaktivirano cepivo (19,5 % v primerjavi s 23,8 %; P=0,02).
Fluenz Tetra is not recommended for women who are pregnant or are breast-feeding. 
Cepiva Fluenz Tetra se ne priporoča pri nosečnicah ali ženskah, ki dojijo.
Depress the plunger With a single motion, depress plunger as rapidly as possible until the dose-divider clip prevents you from going further. 
Pritisnite na bat Z enkratnim pritiskom pritisnite na bat tako hitro, kot lahko, dokler vas ne ustavi sponka za razdelitev odmerka.
- Severe allergic reaction (e.g. anaphylaxis) to eggs or to egg proteins (e.g. ovalbumin). 
- Huda alergijska reakcija (npr. anafilaksija) na jajca ali jajčne beljakovine (npr. ovalbumin).
Nervous system disorders Very common: Headache 
Bolezni živčevja Zelo pogosti: glavobol
In a study (D153-P515) of children 6 to 17 years of age with asthma (trivalent Fluenz: n=1,114, trivalent injectable influenza vaccine: n=1,115), there were no significant differences between treatment groups in the incidence of asthma exacerbations, mean peak expiratory flow rate, asthma symptom scores, or night-time awakening scores. 
V študiji (D153-P515) otrok, starih od 6 do 17 let, ki imajo astmo (trivalentno cepivo Fluenz: n=1.114, trivalentno cepivo proti gripi, ki se injicira: n=1.115), ni bilo posebnih razlik v pojavnosti izbruhov astme, največjega pretoka zraka med izdihom, pogostosti simptomov astme ali pogostosti zbujanja ponoči med zdravljenimi skupinami.
In more than 300 case reports in the AstraZeneca safety database of vaccine administration to pregnant women, no unusual patterns of pregnancy complications or foetal outcomes were observed. 
V več kot 300 kliničnih primerih v varnostni bazi podatkov družbe AstraZeneca ni bilo mogoče opaziti neobičajnih zapletov v nosečnosti ali izidov za plod pri uporabi cepiva pri nosečnicah.
Uncommon: Hypersensitivity reactions (including facial oedema, urticaria and very rare anaphylactic reactions) 
Občasni: preobčutljivostna reakcija (vključno z obraznim edemom, urtikarijo in zelo redko z anafilaktičnimi reakcijami)
• It is recommended that Fluenz Tetra is not given at the same time as influenza-specific antiviral medicines, such as oseltamivir and zanamivir. 
• Priporoča se, da se cepiva Fluenz Tetra ne daje sočasno s protivirusnimi zdravili, specifičnimi za gripo kot sta oseltamivir in zanamivir, ker bo cepivo morda manj učinkovito.
6 to 35 M 1,886 
6 do 35 m 1.886
Fluenz Tetra is not indicated for use in infants and toddlers younger than 24 months (see section 4.2). 
Cepivo Fluenz Tetra ni indicirano za uporabo pri dojenčkih in malčkih mlajših od 24 mesecev (glejte poglavje 4.2).
Several studies against placebo have shown that Fluenz may have some efficacy in adults. 
Več študij, kjer so cepivo primerjali s placebom, je pokazalo, da cepivo Fluenz morda nekoliko učinkuje pri odraslih.
For children who have not previously been vaccinated against seasonal influenza, a second dose should be given after an interval of at least 4 weeks. 
Pri otrocih, ki prej še niso bili cepljeni proti sezonski gripi, je treba drugi odmerek uporabiti, ko minejo vsaj 4 tedni.
Twenty mild to moderately immunocompromised children and adolescents 5 through 17 years of age (receiving chemotherapy and/or radiation therapy or who had recently received chemotherapy) were randomised 1:1 to trivalent Fluenz or placebo. 
Dvajset otrok in mladostnikov z blago do zmerno imunsko oslabelostjo v starosti od 5 do 17 let (ki so prejemali kemoterapijo in/ali radioterapijo ali ki so pred kratkim prejemali kemoterapijo) je bilo randomiziranih 1:1 na trivalentno cepivo Fluenz ali placebo.
Fluenz Tetra is a tetravalent vaccine that contains antigens for four influenza virus strains, an A/(H1N1) strain, an A/(H3N2) strain, and two B strains (one from each lineage). 
Cepivo Fluenz Tetra je štirivalentno cepivo, ki vsebuje antigene za štiri seve virusa gripe: sev A/(H1N1), sev A/(H3N2) in dva seva B (en za vsako linijo).
In 24 HIV-infected children and 25 HIV-negative children 1 through 7 years of age, and in 243 HIV-infected children and adolescents 5 through 17 years of age receiving stable anti-retroviral therapy, the frequency and duration of vaccine virus shedding were comparable to that seen in healthy individuals. 
Pri 24 otrocih okuženih s HIV in 25 otrocih, ki niso bili okuženi s HIV, starimi od 1 do 7 let ter pri 243 otrocih in mladostnikih okuženih s HIV, starimi od 5 do 17 let, ki so prejemali protiretrovirusno zdravljenje, sta bili pogostost in trajanje izločanja cepnega virusa primerljivi z zdravimi osebami.
Safety data regarding use of Fluenz Tetra are based on data from Fluenz Tetra clinical studies in 2,231 children and adolescents 2 to 17 years of age, Fluenz clinical studies in over 29,000 children and adolescents 2 to 17 years of age and Fluenz post-authorisation safety studies in over 84,000 children and adolescents 2 to 17 years of age. 
Varnostni podatki o uporabi cepiva Fluenz Tetra temeljijo na kliničnih študijah cepiva Fluenz Tetra, ki so vključevale 2.231 otrok in mladostnikov starih od 2 do 17 let, kliničnih študijah cepiva Fluenz, ki so vključevale več kot 29.000 otrok in mladostnikov starih od 2 do 17 let in na varnostnih študijah cepiva Fluenz po začetku trženja, ki so vključevale več kot 84.000 otrok in mladostnikov starih od 2 do 17 let.
Musculoskeletal and connective tissue disorders Common: Myalgia 
Bolezni mišično-skeletnega sistema in vezivnega tkiva Pogosti: mialgija
.................................................................................................................per 0.2 ml dose 
.......................................................................................................na 0,2 ml odmerek
Fluenz Tetra has no or negligible influence on the ability to drive and use machines. 
Cepivo Fluenz Tetra nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
Fluenz Tetra is a vaccine to prevent influenza (flu). 
Cepivo Fluenz Tetra je cepivo za preprečevanje gripe.
In the same study, an increased rate of wheezing through 42 days was observed in infants and toddlers 6-23 months of age (5.9% Fluenz versus 3.8% injectable influenza vaccine). 
V isti študiji so opazili povišano stopnjo sopenja v obdobju 42 dni pri dojenčkih in malčkih starih od 6 - 23 mesecev (5,9 % cepivo Fluenz v primerjavi s 3,8 % cepivo proti gripi, ki se injicira).
Position the applicator With the patient in an upright position, place the tip just inside the nostril to ensure Fluenz Tetra is delivered into the nose. 
Namestitev nosnika Ko je oseba v pokončnem položaju, namestite konico nekoliko v nosnico, da zagotovite vnos cepiva Fluenz Tetra v nos.
Table 1 Fluenz Efficacy in Placebo Controlled Paediatric Studies 
Preglednica 1 Učinkovitost cepiva Fluenz v pediatričnih študijah, kontroliranih s placebom
Do not remove dose-divider clip at the other end of the applicator. 
Ne odstranite sponke za razdelitev odmerka na drugi strani nosnika.
Reassortant influenza virus* (live attenuated) of the following four strains**: 
Novi virus gripe* (živ oslabljen) naslednjih štirih sevov**:
Immunogenicity was evaluated by comparing geometric mean titres (GMTs) of strain-specific serum haemagglutination inhibition (HAI) antibodies post dosing. 
Imunogenost je bila ocenjena s primerjanjem geometričnega povprečja titrov (GMTs - geometric mean titres) serumskih protiteles specifičnih za sev, ki zavirajo hemaglutinacijo (HAIhaemagglutination inhibition antibodies) po uporabi.
What Fluenz Tetra is and what it is used for What you need to know before you are given Fluenz Tetra How Fluenz Tetra is given 
Kaj je cepivo Fluenz Tetra in za kaj ga uporabljamo Kaj morate vedeti, preden boste prejeli cepivo Fluenz Tetra Kako uporabljati cepivo Fluenz Tetra Možni neželeni učinki
Paediatric studies 
Pediatrične študije
The suspension is colourless to pale yellow, clear to opalescent with a pH of approximately 7.2. 
Suspenzija je brezbarvna do bledorumena, bistra do opalescentna ter ima pH približno 7,2.
Pack size of 1 or 10. 
Pakiranje z 1 nosnikom ali 10 nosniki.
No data exist regarding the possible effects of Fluenz Tetra on male and female fertility. 
Podatkov o morebitnem vplivu cepiva Fluenz Tetra na plodnost pri moških in ženskah ni.
The recommended dose for children and adolescents is 0.2 ml Fluenz Tetra, administered as 0.1 ml in each nostril. 
Priporočeni odmerek je tako za otroke kot za mladostnike 0,2 ml cepiva Fluenz Tetra, danega po 0,1 ml v vsako nosnico.
In a study of children and adolescents 9 to 17 years of age with moderate to severe asthma (trivalent Fluenz: n=24, placebo: n=24), the primary safety criterion, change in percent predicted forced expiratory volume in 1 second (FEV1) measured before and after vaccination, did not differ between treatment arms. 
V študiji otrok in mladostnikov starih od 9 do 17 let, ki imajo zmerno do hudo astmo (trivalentno cepivo Fluenz: n=24, placebo: n=24) se primarni varnostni kriterij, tj. sprememba v odstotkih napovedanega forsiranega ekspiracijskega volumna v prvi sekundi (FEV1) izmerjenega pred in po cepljenju, ni razlikoval v krakih.
If influenza antiviral agents and Fluenz Tetra are administered concomitantly, revaccination should be considered based on clinical judgement. 
Pri sočasni uporabi protivirusnih zdravil in cepiva Fluenz Tetra je treba razmisliti o revakcinaciji glede na klinično presojo.
The co-administration of Fluenz Tetra with inactivated vaccines has not been studied. 
Sočasne uporabe cepiva Fluenz Tetra z inaktiviranimi cepivi niso preučevali.
The effectiveness of Fluenz and Fluenz Tetra in preventing influenza illness in immunocompromised individuals has not been evaluated. 
Učinkovitost cepiv Fluenz in Fluenz Tetra pri preprečevanju obolevanja za gripo imunsko oslabelih oseb ni bila ocenjena.
Table 2 Fluenz Relative Efficacy in Active-controlled Paediatric Studies with Injectable Influenza Vaccine 
Preglednica 2 Relativna učinkovitost cepiva Fluenz v aktivno kontroliranih pediatričnih študijah s cepivom proti gripi, ki se injicira